AGREEMENTS BETWEEN PARTIES Sample Clauses

AGREEMENTS BETWEEN PARTIES. A. Business Practices Associated with NRC Work Performed by DOE Laboratories All NRC funded work performed at the DOE laboratories shall be administered in accordance with standard NRC and DOE policies and procedures as agreed to and implemented by each agency. The DOE policies governing work for others are set forth in DOE order 481.1, Work for Others (Non-Department of Energy Funded Work). The NRC policies for work placed at DOE laborctories are set forth in NRC Management Directive 11.7, NRC Procedures for Placement and Monitoring of Work with the U.S. Department of Energy (DOE).

AGREEMENTS BETWEEN PARTIES. The terms of sampling recognize the date of sample retrieval from the above subject property to have commenced on [Date] at [Time] Paragraph 1 The Parties Understand and Voluntarily Agree as follows:

AGREEMENTS BETWEEN PARTIES. Any and all existing agreements between Purchasers and Seller, Exxxxx and Seller, and Bxxxxxx and Seller, will be terminated. At closing, Exxxxx and Bxxxxxx shall each enter into Non-Competition, Non-Disclosure and Non-Solicitation Agreements with the Company.

AGREEMENTS BETWEEN PARTIES. This Lease contains all of the agreements and understandings of the parties and cannot be amended or modified except by a written agreement.

AGREEMENTS BETWEEN PARTIES. (a) As of the Effective Date, Genentech and Novartis each represent and warrant to Tanox that aside from the agreements listed in Part A of Schedule C, agreements between all three of the Parties and agreements with one or more Third Parties which are related to and entered into solely in the ordinary course of the implementation of development or commercialization activities regarding Anti-IgE Antibodies or Anti-IgE Products pursuant to the Outline of Terms, the Original JCA or the Original D&L Agreement, or which are related to litigation or litigation procedures between the Parties or anticipated litigation with any Third Party, there are no agreements between Genentech and Novartis which remain in effect after the Effective Date relating to the clinical development, manufacture or commercialization (including, without limitation, with respect to the sharing of costs or inter-Party transfers or sales of Anti-IgE Product) of Anti-IgE Antibodies, Anti-IgE Products or other Antibody products which are known to directly or indirectly, operate through or within the IgE pathway to inhibit or otherwise interact with IgE;

AGREEMENTS BETWEEN PARTIES